• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

N Biotechnol . FN3-based Monobodies that Bind to the Receptor Binding Domain of the SARS-CoV-2 Spike Protein

tetano

Editor, Senior Moderator
N Biotechnol


. 2021 Feb 5;S1871-6784(21)00015-7.
doi: 10.1016/j.nbt.2021.01.010. Online ahead of print.
FN3-based Monobodies that Bind to the Receptor Binding Domain of the SARS-CoV-2 Spike Protein


Christina J Miller[SUP] 1 [/SUP], Jennifer E McGinnis[SUP] 1 [/SUP], Michael J Martinez[SUP] 1 [/SUP], Guangli Wang[SUP] 2 [/SUP], Jian Zhou[SUP] 3 [/SUP], Erica Simmons[SUP] 4 [/SUP], Tohti Amet[SUP] 4 [/SUP], Sanofar J Abdeen[SUP] 4 [/SUP], James W Van Huysse[SUP] 4 [/SUP], Ronald R Bowsher[SUP] 4 [/SUP], Brian K Kay[SUP] 5 [/SUP]



Affiliations
Free PMC article

Abstract

A phage library displaying 10[SUP]10[/SUP] variants of the fibronectin type III (FN3) domain was affinity selected with the biotinylated form of the receptor binding domain (RBD, residues 319-541) of the SARS-CoV-2 virus spike protein. Nine binding FN3 variants (i.e. monobodies) were recovered, representing four different primary structures. Soluble forms of the monobodies bound to several different preparations of the RBD and the S1 spike subunit, with affinities ranging from 3 to 14 nM as measured by bio-layer interferometry. Three of the four monobodies bound selectively to the RBD of SARS-CoV-2, with the fourth monobody showing slight cross-reactivity to the RBD of SARS-CoV-1 virus. Examination of binding to the spike fragments and its trimeric form revealed that the monobodies recognise at least three overlapping epitopes on the RBD of SARS-CoV-2. While pairwise tests failed to identify a monobody pair that could bind simultaneously to the RBD, one monobody could simultaneously bind to the RBD and the ectodomain of the cellular receptor angiotensin converting enzyme 2 (ACE2). All four monobodies successfully bound the RBD after overexpression in Chinese hamster ovary (CHO) cells as fusions to the Fc domain of human IgG1.

Keywords: SARS-CoV-1 virus; SARS-CoV-2 virus; affinity selection; angiotensin-converting enzyme; coronavirus; monobody; phage-display; receptor; spike protein.
 
Back
Top Bottom